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Abstract
Purpose: The PI3K/AKT/P70S6K pathway is an attractive therapeutic target in ovarian
and uterine malignancies due to its high rate of dysregulation and key roles in tumor
growth. Here, we examined the biological effects of MSC2363318A, which is a novel
inhibitor of AKT1, AKT3, and P70S6K.
Experimental Design: Orthotopic murine models of ovarian and uterine cancer were
utilized to study the effect of MSC2363318A on survival and regression. Moreover, in
vitro experiments (MTT, Western blot analysis, plasmid transfection, and reverse phase
protein array [RPPA]) were carried out to characterize underlying mechanisms and
potential biomarkers of response.
Results: MSC2363318A decreased tumor growth and metastases in multiple murine
orthotopic models of ovarian (SKOV3ip1, HeyA8, and Igrov1) and uterine (Hec1a)
cancer and reduced proliferation (Ki67) and angiogenesis (CD31) indices and
increased cell death (cleaved caspase-3) markers. Synergy between MSC2363318A
and paclitaxel was observed in vitro in protected (IC50 ≥ 5 µM) cell lines. RPPA
identified YAP1 as a candidate marker to predict cell lines that were most sensitive to
MSC2363318A (R=0.675, p=0.0015). After establishment of a bevacizumab resistant
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endothelial cell line, RF-24, we demonstrate that resensitization to bevacizumab occurs
with the addition of MSC2363318A.
Conclusions: MSC2363318A has therapeutic efficacy in multiple pre-clinical models of
ovarian and uterine cancer. These findings support clinical development of dual
AKT/P70S6K inhibition.

vii

Table of Contents
Approvals…………………………………………………………………………………….i
Title…………………………………………………………………………………………...ii
Dedication…………………………………………………………………………………...iii
Acknowledgements………………………………………………………………………...iv
Abstract………………………………………………………………………………..…….vi
Table of Contents…………………………………………………………………………..viii
List of Figures………………………………………………………………………………..ix
List of Tables……………………………………………………………………………..…xii
Background and Introduction……………………………………………………………...1
Hypotheses and Specific Aims…………………………………………………………..13
Methods…………………………………………………………………………………….14
Results……………………………………………………………………………………...24
Discussion………………………………………………………………………………….61
Bibliography………………………………………………………………………………..72
Vita……………………………………………………………………………………….....83

viii

List of figures
Figure 1. Laparoscopic assessment of disease burden involving the bilateral ovaries
and peritoneum.

2

Figure 2. Overview of the PI3K/AKT/mTOR pathway.

9

Figure 3. PI3K/AKT pathway has genes altered in 47% (n=272) of high grade serous
ovarian cancer cases from The Cancer Genome Atlas.

24

Figure 4. PI3K/AKT pathway has genes altered in 90% (n=216) of uterine cases from
The Cancer Genome Atlas.

25

Figure 5. Dose finding experiments with MSC2363318A in an ovarian orthotopic
model.

26

Figure 6. Maximum tolerated dose experiment with MSC2363318A monotherapy and in
combination with paclitaxel on non-tumor bearing mice.

27

Figure 7. Effects of MSC2363318A on ovarian tumor growth.

28

Figure 8. Effects of MSC2363318A on ovarian tumor growth in a second orthotopic
model.

29

Figure 9. Effects of MSC2363318A on uterine tumor growth.

31

Figure 10. Effect of MSC2363318A on proliferation and apoptosis on ovarian
tumors.

33

Figure 11. Effect of MSC2363318A on apoptosis, proliferation, and angiogenesis on
ovarian tumors.

34

Figure 12. Effect of MSC2363318A on proliferation and apoptosis on uterine
tumors.

35

Figure 13. Effects of MSC2363318A on ovarian cancer cell lines.

38

ix

Figure 14. Effects of MSC2363318A on uterine cancer cell lines.

39

Figure 15. Effects of MSC2363318A on resistant ovarian and uterine cancer cell line
proliferation.

40

Figure 16. Effects of MSC2363318A on sensitive ovarian and uterine cancer cell line
proliferation.

40

Figure 17. Effect of MSC2363318A concentration on downstream markers in the
PI3K/AKT pathway.

41

Figure 18. Effect of time on MSC2363318A on downstream markers in the PI3K/AKT
pathway.

42

Figure 19. In vitro effects of MSC2363318A and paclitaxel in resistant ovarian and
uterine cancer cell lines.

43

Figure 20. In vitro effects of MSC2363318A and paclitaxel in sensitive ovarian and
uterine cancer cell lines.

44

Figure 21. In vitro effects of MSC2363318A and paclitaxel in ovarian and uterine
cancer cell lines on apoptosis.

45

Figure 22. Differential expression of proteins in the PI3K/AKT/P70S6 signaling pathway
after MSC2363318A treatment as detected by reverse-phase protein array.

46

Figure 23. Upregulated pro-angiogenic signaling molecules by a network
overlaid with the ratio of resistant to sensitive total protein change using
Ingenuity Pathway Analysis.

47

Figure 24. Differential expression of angiogenic proteins in the PI3K/AKT/P70S6
signaling pathway after MSC2363318A treatment as detected by
reverse-phase protein array.

48

x

Figure 25. Logarithmic ratio values for YAP1 and pYAP1 in cancer cell lines.

49

Figure 26. Western blot validation using samples submitted for RPPA.

50

Figure 27. Correlation between YAP1 and MSC2363318A IC50 in ovarian and uterine
cancer cell lines.

51

Figure 28. Characterization of YAP1 overexpressing clones and effects on apoptosis
after MSC2363318A treatment.

52

Figure 29. In vitro effects of MSC2363318A in combination with anti-angiogenic therapy
in a sensitive endothelial cell line.

53

Figure 30. In vitro effects of MSC2363318A in combination with anti-angiogenic
therapy in a resistant endothelial cell line.

54

Figure 31. Effect of treatment with MSC2363318A in combination with bevacizumab on
proliferation and downstream markers.

55

Figure 32. Effect of MSC2363318A IC50 in resistant and sensitive RF-24 cells with
and without bevacizumab.

56

Figure 33. In vivo effects of MSC2363318A on angiogenesis in combination with
paclitaxel.

57

Figure 34. In vivo effects of MSC2363318A in combination with anti-angiogenic
therapy in an ovarian orthotopic model.

59

Figure 35. Effects of MSC2363318A and bevacizumab on angiogenesis, proliferation
and apoptosis in an ovarian orthotopic model.

60

xi

List of Tables
Table 1. Five year overall survival in ovarian cancer patients by stage at
diagnosis.

6

Table 2. Five year overall survival in uterine cancer patients by stage at
diagnosis.

7

Table 3. Mutation status of ovarian and uterine cancer cell lines.

37

Table 4. Top 10 networks in resistant to sensitive ovarian and uterine cancer
cell lines.

46

xii

Introduction
Epidemiology and standard of care for ovarian and uterine malignancy
Ovarian cancer remains the seventh most common malignancy worldwide and
represents approximately 4% of new cancer cases diagnosed each year in women [1].
It is the eighth most common cause of cancer deaths. The estimated five year overall
survival of newly diagnosed ovarian cancer depends on the stage of disease at
diagnosis. Epithelial carcinoma is the most common histologic type of ovarian cancer
and accounts for 90% of cases. The histologic subtypes include high grade serous,
which accounts for 70-80% of cases, endometrioid, clear cell, mucinous, and low grade
serous [2,3]. Due to a lack of effective screening, vague symptomology, and advanced
disease presentation, patients with advanced stage IIIC and stage IV disease have an
overall survival of 32.5 and 18.6%, respectively [4].
In developed countries, uterine cancer is the most common malignancy and the
second most common worldwide [1]. The majority of women (68%) are diagnosed at
an earlier stage when disease is confined to the uterus [5]. This is primarily due to
symptoms of postmenopausal bleeding. Adenocarcinoma of the uterus is the most
common histologic subtype of uterine cancer and is broadly classified into type 1 or
type 2 tumors, which differ in their incidence, responsiveness to estrogen, and clinical
behavior [6,7]. Type 1 tumors are low grade (grade 1 or 2), endometrioid histology,
and comprise the majority of adenocarcinomas (approximately 80%).
primarily estrogen dependent and have a favorable prognosis.

These are

In contrast, type 2

tumors consist of high grade endometrioid histology (grade 3) and non-endometrioid
histologies, including serous, clear cell, squamous, undifferentiated, mucinous and
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transitional cell types. These tumors are not estrogen dependent and have a more
aggressive clinical course.
Staging for both diseases can be classified generally to the location of the
primary disease at diagnosis and the presence of distant metastases.

Generally

speaking, in stage 1 disease, tumor growth is limited to the primary disease site (either
the ovary or uterus). In stage 2 disease, tumor has spread to other disease sites within
the pelvis for ovary or to the vagina in uterine cancer. In stage 3 disease, tumor has
spread intra-abdominally outside of the pelvis and/or to the retroperitoneal lymph nodes
(Figure 1).

Stage 4 comprises distant metastases including parenchymal liver

involvement or malignant pleural effusions [8].
Figure 1. Laparoscopic assessment of disease burden involving the bilateral
ovaries and peritoneum. Photo courtesy of Alpa Nick, M.D.

Cytroreductive surgery to no gross residual disease and comprehensive surgical
staging followed by adjuvant taxane- and platinum based chemotherapy regimens
2

remain the mainstay of upfront treatment [9] for ovarian cancer.

Despite the

effectiveness of frontline treatment, the majority (62%) of women will recur and
ultimately die of their disease. In women with stage III or IV disease, 80-85% will recur.
Second-line chemotherapy or surgery in selected cases is offered to women with
recurrent disease. More recently, anti-angiogenic therapies [10,11], PARP inhibitors in
women with a BRCA mutation [12,13], and genomic testing of the tumor [14,15] have
been employed to improve progression free and overall survival. Bevacizumab and
olaparib were the first two biologic therapies approved for ovarian cancer.
The administration of bevacizumab as a frontline agent in women with newly
diagnosed ovarian cancer has been evaluated by two randomized controlled studies:
GOG218 and ICON7. In GOG218, women were randomized to receive: (1) standard
chemotherapy with carboplatin and paclitaxel; (2) bevacizumab plus standard
chemotherapy for six cycles followed by placebo until month 15, or (3) bevacizumab
plus standard chemotherapy followed by bevacizumab until month 15. There was a
significant increase in progression free survival of patients that received bevacizumab
plus chemotherapy followed by bevacizumab, but there was no improvement of overall
survival [16].

ICON7 randomized women newly diagnosed with ovarian cancer to

standard carboplatin or paclitaxel for six cycles with or without bevacizumab during
chemotherapy and then as a maintenance treatment for 12 additional cycles. While
there was a significant improvement in progression free survival in the women who
received bevacizumab (24 versus 22 months), there was no difference in overall
survival [17].
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The use of bevacizumab in the setting of relapsed disease has also been
evaluated. In GOG17D, women (n=62) with platinum-resistant disease were treated
with bevacizumab, and two patients had complete responses and 11 had partial
responses. Median progression free survival and overall survival were 4.7 and 17
months, respectively [10]. In another Phase II study, women with platinum-resistant
ovarian cancer received single agent bevacizumab and median progression free
survival was 4.4 months. Median survival duration was 10.7 months [18].
In December 2014, the Food and Drug Administration granted accelerated
approval for olaparib as a treatment for women with BRCA1 or BRCA2 mutations
following three or more lines of previous chemotherapy. This approval came from
Study 19, which evaluated women with BRCA-associated platinum-sensitive ovarian
cancer.

This trial included nearly 300 women with recurrent disease who were

randomized to receive treatment with olaparib or placebo. There was a significant
improvement in progression free survival (eight versus five months) in the women who
were treated with olaparib [12]. An interim analysis did not show an overall survival
benefit. A separate analysis of patients with a known BRCA mutation suggested that
the clinical benefit was the highest in this subset of patients, with a significant
improvement in progression free survival (11 versus 4 months) and a trend toward an
improvement in overall survival [13].
Hysterectomy, bilateral salpingo-oophorectomy, with pelvic or para-aortic lymph
node dissection (or sentinel lymph node assessment) is the recommended staging
procedure for patients with uterine cancer [19]. In women that present with pelvic or
intra-abdominal disease, complete cytoreduction has been associated with prolonged
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overall survival [20]. Adjuvant treatment of women following surgery depends on their
individual risk of recurrence and the presence of persistent disease. Women are
stratified into low-, intermediate-, and high-intermediate, and high risk for recurrence
and may receive combination taxane- and platinum based chemotherapy with or
without radiation.
The estimated five year survival of newly diagnosed ovarian and uterine cancer
patients can be broken down by FIGO stage. Most ovarian cancers are of epithelial
origin and present with high grade and late stage; the five year overall survival is
dismal, around 30%. Early stage disease uterine cancer portends a five year overall
survival of 90%, but higher stage disease has five year overall survivals that are similar
to that of ovary (Tables 1-2).

5

Table 1.

Five year overall survival in ovarian cancer patients by stage at

diagnosis [8].
FIGO stage

5-year Overall Survival (%)

IA

89.6

IB

86.1

IC

83.4

IIA

70.7

IIB

65.5

IIC

71.4

IIIA

46.7

IIIB

41.5

IIIC

32.5

IV

18.6

6

Table 2.

Five year overall survival in uterine cancer patients by stage at

diagnosis [19].
FIGO stage

5-year Overall Survival (%)

IA

90

IB

78

II

74

IIIA

56

IIIB

36

IIIC1

57

IIIC2

49

IVA

22

IVB

21

The Cancer Genome Atlas (TCGA) provides an important resource for
understanding the molecular pathogenesis of these malignancies. Using 489 high
grade serous ovarian cancer samples, TCGA analysis showed the high prevalence of
TP53 mutations in almost all of the samples (96%). Other recurrent somatic mutations
were found in NF1, BRCA1, BRCA2, RB1, and CDK12 genes [21]. Further analysis,
found that homologous recombination is frequently abnormal in about half of the cases,
with NOTCH and FOXM1 cell signaling also altered [21]. From the uterine cancer
TCGA analysis, uterine serous tumors had frequent TP53 mutations, extensive copy
number alterations, and low levels of estrogen and progesterone receptors. In the
endometrioid tumors that were examined, there were much fewer copy number
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alterations and mutations in TP53, but there were frequent mutations in PTEN,
CTNNB1, PIK3CA, ARID1A, KRAS, and ARID5B. A subset of endometrioid tumors had
increased transversion mutation frequency in POLE [22].
In women with recurrent, refractory disease, new therapeutic agents are needed
to impact survival and potentially cure women of metastases. Multiple classes of
targeted therapies have been developed to target the tumor cells in these solid
malignancies and the cells within the tumor microenvironment.

Within the

microenvironment, targeting the vasculature with anti-vascular endothelial growth factor
(VEGF) therapy with a commonly used monoclonal antibody, bevacizumab, has shown
to induce partial responses and/or stable disease [10]. Bevacizumab binds VEGF,
preventing it from binding to VEGF receptors.

Because of the poor prognosis of

ovarian and type 2 endometrial cancers with little improvement in the outcomes of
women with standard surgery and adjuvant chemotherapy, a better understanding of
the complex interplay of the tumor microenvironment with aberrant tumor cell signaling
is warranted.

The PI3K/AKT/mTOR pathway and malignancy
The PI3K/AKT/mTOR pathway controls important cellular processes necessary
for tumorigenesis and metastasis including survival, proliferation, metabolism,
regulation of cell cycle, angiogenesis, and genomic instability (Figure 2) [23]. This
pathway plays a pivotal role in many malignant features involved in tumor pathogenesis
and is intimately linked with most of the hallmarks of cancer [24]. Genomic studies
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suggest that aberrations within this signaling pathway are among the most frequently
altered in malignancies.
Figure 2. Overview of the PI3K/AKT/mTOR pathway.

PI3K is a major downstream effector of G-coupled protein receptors and tyrosine
kinase receptors. Three classes of PI3K have been recognized: (1) Class IA PI3K
includes IA PIK3α, β, and δ, all of which are activated by receptors that have receptor
tyrosine kinase activity; (2) Class IB PI3K includes PI3Kγ, which are subsequently
activated by G-coupled protein receptors. The Class IA PI3Ks are heterodimers and
consist of p110 catalytic and p85 regulatory subunits.

The three genes, PIK3CA,

PIK3CB, and PIK3CD, encode the three classes of 1A p110 isoforms (α, β, and δ). Of
these three genes, only PIK3CA is mutated frequently in human malignancies [23].
Activated PI3K phosphorylates phosphatidylinositol 4,5-bisphosphate (PI(4,5)P2;
PIP2) to generate phosphatidylinositol (3,4,5)-triphosphate (PI(3,4,5)P3; PIP3). AKT is
9

recruited to the cell’s plasma membrane where it can be phosphorylated at its
serine473 or threonine308 residues. The tumor suppressor, PTEN, and INPP4B are
responsible for the negative regulation of activation. PTEN dephosphorylates PIP3 at
the 3-position phosphate of PIP3, which produces PIP2. INPP4B is responsible for the
dephosphorylation of phosphatidylinositol (3,4)-bisphosphate (PI(3,4)P2) to form PI(3)P
at the 4-position phosphate group [25]. Constitutive activation of AKT results from the
loss of either PTEN or INPP4B, which them leads to the accumulation of PIP3 or
PI(3,4)P2, respectively. Phosphorylated or activated AKT phosphorylates mTOR at the
serine2448 residue, which activates mTORC1.

Indirectly, AKT can also active

mTORC1 through phosphorylation of the tuberous sclerosis complex (TSC2).
Phosphorylated TSC2 leads to the inactivation of the functional TSC1/TSC2 complex.
However, when this complex is activated, TSC2 enables the conversion of Rheb-GTP
(Ras homolog enriched in brain-GTP) to Ras-GDP, which then inactivates mTORC1.
Once TSC2 is phosphorylated or inactivated by AKT, Rheb-GTP is responsible for
stimulating the activity of mTORC1. The other complex, mTORC2, is activated through
an unclear mechanism, but PI3K may be responsible for its activation [26].

Once

activated, mTORC2 phosphorylates other kinases, such as AKT, kinases present in the
serum and glucocorticoid, and kinases that regulate lipogenesis, the metabolism of
glucose, influence apoptosis, and are involved in the cellular cytoskeleton.
Once phosphorylated, mTORC1 phosphorylates ribosomal S6 kinase-1, which
regulates protein translation and 4EBP-1, the eukaryotic translation initiation factor.
S6K-1 activation then leads to downstream translation of mRNA encoding ribosomal
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proteins, factors responsible for elongation, and proteins responsible for cell cycle
progression [27].

PI3K/AKT pathway alterations in ovarian and uterine cancer
Genetic and/or epigenetic changes lead to activation of the PI3K/AKT signaling
pathway in multiple cancers. Ovarian, type 1, and type 2 uterine cancers exhibit
alterations in this pathway [21,28]. Additionally, previous analyses have found this
pathway to be activated in half of high grade serous ovarian carcinomas. The PIK3CA
gene, which encodes the catalytic isoform p100α, is a commonly mutated oncogene,
affecting over 30% of solid tumors [29]. PTEN, which encodes phosphatase and tensin
homolog, is one of the most frequently mutated tumor suppressor genes and is
frequently suppressed or downregulated leading to activation of the PI3K/AKT signaling
pathway [30]. Frequent aberrations of this pathway in ovarian cancer include mutations
in PTEN [31] or hypermethylation of the promoter [32], loss of heterozygosity at the
INPP4B locus [25], somatic mutations in mTOR and AKT1 [33], amplification of AKT2
[34], somatic activating mutations in the PIK3CA gene [35], and activating mutations in
the PIK3R1 gene [36].
Uterine cancers harbor the highest rates of PI3K/AKT pathway alterations
[37]. PTEN mutations, often occur early in uterine cancer pathogenesis, are frequently
identified in type 1 tumors, and have been identified in 34-55% of endometrial cancers
[22]. Other frequently identified pathway mutations in uterine cancer include PIK3CA
(25-40%), PIK3R1 (15-25%), and less commonly, AKT1-3 mutations (2-5%)
[38,39,40,41].

11

The tumor microenvironment and the PI3K/AKT pathway
Almost all cells within the tumor microenvironment are influenced by the
PI3K/AKT signaling pathway. Tumor cells secrete pro-angiogenic factors including
VEGF that activate quiescent endothelial cells.

New vasculature originates from

existing blood vessels from proliferation and activated endothelial cells through vessel
co-option [42]. Additionally, cells derived from the bone marrow including monocytes,
endothelial progenitor cells, and mast cells also promote the new growth and
maintenance of blood vessels [43]. The PI3Ks have been established as controls of
hypoxia-inducible factor (HIF)-1α expression and VEGF secretion [44,45,46]. Within
the endothelial cells, the PI3Ks are responsible for the transduction of signals that are
downstream of angiogenic receptors. These include receptors in the VEGF family such
as VEGFR-1/Flt-1, VEGFR-2/Flk-1, and VEGFR3 [47,48,49]. Upon phosphorylation of
AKT, downstream effects are activated including migration of endothelial cells,
proliferation, and tubulogenesis. Additionally, other endothelial cell stimuli and ligands
have been shown to activate the endothelial cell including angiopoietin-1, insulin,
insulin-like growth factor-1, hepatocyte growth factor, estrogen, fluid shear stress,
reactive oxygen species, and corticosteroids [50,51,52,53,54,55,56,57]. The activation
of AKT by VEGF within endothelial cells requires matrix attachment and promotes
endothelial cell viability [58].
Targeting the cell microenvironment, specifically the PI3K/AKT pathway, within
endothelial cells, may provide a rational approach to overcoming resistance to antiangiogenic therapy in the clinical setting.

12

The high prevalence of these molecular alterations in ovarian and uterine
cancers, combined with the druggability of the PI3K/AKT pathway in the tumor cells
and the microenvironment, represents an important therapeutic opportunity.

Hypothesis and specific aims:

Hypothesis: Dual inhibition of AKT and P70S6K will reduce tumor growth by
decreasing angiogenesis, inhibiting tumor cell proliferation, and promoting
apoptosis in ovarian and uterine cancer cells.
•

Specific Aim 1:

To determine the prevalence of PI3K/AKT/P70S6

alterations in ovarian and uterine cancer.
•

Specific Aim 2: To assess the efficacy of an AKT/P70S6 inhibitor
(MSC2363318A) in combination with chemotherapeutic agents (taxanes
and bevacizumab) in vitro and in vivo using well-established mouse
models of ovarian carcinoma.

•

Specific Aim 3: To determine the mechanisms underlying the biological
responses to MSC2363318A-based therapy.

13

Materials and Methods

Cell line maintenance and siRNA transfections
All cell lines were maintained in 5% CO2 at 37 °C. Ovarian cancer (A2780, ES2,
HeyA8, Igrov1, Ovcar3, Ovcar4, Ovcar5, Ovcar8, Ovca432, and SKOV3ip1), uterine
cancer (AN3CA, Hec1A, Hec1B, Hec265, Ishikawa, KLE, RL95-2, Spec2 SKUT2,
RL95-2 and KLE), and endothelial (RF-24) cells were obtained from the American Type
Culture Collection. A2780, ES2, HeyA8, Igrov1, Ovcar3, Ovcar4, Ovcar8, Ovca432,
SKOV3ip1, and Hec265 were maintained in RPMI 1640 supplemented with 10–15%
fetal bovine serum (FBS) and 0.1% gentamicin sulfate (GeminiBioproducts, Calabasas,
CA). Endometrial cell lines were maintained and propagated in MEM (Ishikawa),
McCoy's 5A (Hec1A), and 1:1 D-MEM:F12 (KLE and RL95-2) media supplemented
with 10% fetal bovine serum and 0.1% gentamicin sulfate. Spec2 was maintained in a
1:1 mixture of DMEM and Ham's F-12 medium supplemented with 10% fetal bovine
serum, L-glutamine, sodium pyruvate, nonessential amino acids, and a 2-fold vitamin
solution (Life Technologies Laboratories). Ovcar5 and SKUT2 cells were maintained in
D-MEM with 10% and 20% FBS, respectively. Hec1b cells were maintained in MEM
supplement supplemented with 10% FBS, glutamine, sodium pyruvate and amino
acids. RF-24 cells were maintained in D-MEM supplemented with pyruvate, amino
acids, and penicillin/streptomycin.
Cell lines were obtained within one year of the work described, and per
institutional policy (MD Anderson policy ACA#1044) cell line authentication was
performed at least once per year. In this case, authentication was performed within six
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months of the work described. Authentication was performed by the short tandem
repeat method using the Promega Power Plex 16HS kit (Promega). Somatic mutations
were detected using a Sequenom MALDI TOF MassArray system (Sequenom).
Mycoplasma detection was performed using the MycoAlert Kit (Lonza), and all in
vitro experiments were conducted with 60-80% confluent cultures.

In vivo models
Female athymic nude mice were purchased from Taconic Farms (Hudson, NY)
as previously described [59]. The mice were housed and cared for according to
guidelines set forth by the United State Public Health Service policy on Human Care
and Use of Laboratory Animals and the American Association for Accreditation of
Laboratory Animal Care. The University of Texas MD Anderson Cancer Center
Institutional Animal Care and Use Committee approved and supervised all studies. All
animals were 8–12 weeks old at the time of injection.
Prior to injection of cells for animal experiments, cells were harvested using
trypsin-EDTA, FBS-containing media was added, then cells were washed and
resuspended in Hanks’ balanced salt solution (HBSS; Gibco, Carlsbad, CA) before
injection. For the Igrov1 (1 × 106 cells in 200 μl of HBSS), SKOV3ip1 (1 × 106 cells in
200 μl of HBSS) and HeyA8 (250 x 103 in 200 μl of HBSS) model, cells were injected
intraperitoneally For the uterine cancer model, Hec1A cells were injected into the right
uterine horn (4 × 106 cells in 100 μl of HBSS ). For the intra-uterine injections, mice
were anaesthetized with ketamine and administered buprenorphine (0.1 mg/kg)
subcutaneously. An incision in the midline was made and using blunt dissection the
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right uterine horn identified. A 30-gauge needle on a 1-ml tuberculin syringe was used
to inject the cell suspension directly into the uterus. After injection, the incision was
closed in two layers with 0-0 Vicryl and surgical clips, and the mouse was returned to a
cage until fully recovered.
For

all

experiments,

mice

were

treated

by

oral

gavage

daily

(25

mg/kg). MSC2363318A was reconstituted in 0.5% Hydroxypropyl Methylcellulose
(Hypromellose 2208, Spectrum Chemical), 0.25% Tween 20 in 100 mM Citrate buffer
pH3 (Teknova). For the SKOV3ip1, Hec1A, HeyA8, and Igrov1 models, treatments
began seven to days after cell injection and continued for approximately four to six
weeks. Mice were treated with paclitaxel (4 mg/kg) once weekly via intraperitoneal
injection

and

bevacizumab

(6.25

mg/kg)

twice

weekly

via

intraperitoneal

injection. Once mice in any group became moribund, all mice were sacrificed and
necropsied. Tumors were harvested, and weight, number and location of metastatic
nodules were recorded. Tumor tissue was preserved and fixed in formalin for paraffin
embedding, frozen in optimal cutting temperature media to prepare frozen slides, or
snap-frozen for lysate preparation.

Immunoblotting
Lysates were prepared using modified RIPA buffer (50 mM Tris–HCl (pH 7.4),
150 mM

NaCl,

1%

Triton,

0.5%

deoxycholate)

plus

25 μg ml−1 leupeptin,

10 μg ml−1 aprotinin, 2 mM EDTA and 1 mM sodium orthovandate. A BCA Protein Assay
Reagent kit (Pierce Biotechnology, Rockford, IL) was used to determine the protein
concentrations. Lysates were loaded and then separated on SDS–PAGE. Transfer of
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protein was achieved through use of a nitrocellulose membrane by wet electrophoresis
(Bio-Rad Laboratories, Hercules, CA) overnight, blocked with 5% BSA for one hour and
then incubated at 4°C overnight with primary antibody (p-ribosomal S6 protein 1:1,000,
pAKT 1:1000, AKT 1:1000, YAP1 (1:1000); p-p70S6k 1:500, p-70S6k 1:500) (Cell
signaling, Danvers, MA)). After washing thrice with tris-buffered saline with Tween 20,
membranes were incubated with horseradish peroxidase-conjugated horse anti-Mouse
or Rabbit IgG (1:2,000, GE Healthcare, UK) for one hour. Visualization of horseradish
peroxidase was performed using an enhanced chemiluminescence detection kit (Pierce
Biotechnology). The blots were probed with an antibody specific for β-actin (0.1 μg/mL;
Sigma) to confirm equal loading.

Quantitative real-time PCR
Total RNA was isolated using the Qiagen RNeasy kit (Qiagen, CA) and
quantified. Complementary DNA was synthesized using 1,000 ng of RNA and a Verso
cDNA kit (Thermo Scientific, PA), as per the manufacturer’s instructions. A 7500 Fast
Real-Time PCR System (Applied Biosystems, CA) with SYBR green-based real-time
PCR was used for analysis of mRNA levels for all genes. Specific primers for YAP1
were F-CAAGAAAGCAGGCTCACAGAA, R-GCTGGGTGTTAGGGCTTCG; and 18S
F-CGCCGCTAGAGGTGAAATTC, R-TTGGCAAATGCTTTCGCTC were used; 18S
was used as a housekeeping gene. PCR was done with reverse-transcribed RNA and
100 ng/μL of sense and antisense primers in a total volume of 20 μL. Each cycle
consisted of 15 seconds of denaturation at 95°C and 1 minute of annealing and
extension at 60°C (40 cycles).

17

Cell viability assay
Cell viability assays were performed by testing cell's ability to reduce the
tetrazolium

salt

[3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-

sulfophenyl)-2H-tetrazolium, inner salt] to a formazan. Cells were seeded in a 96-well
plate and treated for 96 hours with increasing concentrations of MSC2363318A and
paclitaxel and 72 hours with increasing concentrations of bevacizumab. After 96 hours,
cells were incubated with 0.15% 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium
bromide (MTT) for 2 hours at 37°C. The supernatant was removed, cells were
dissolved in 100-μL DMSO, and the absorbance at 540 nm was recorded.

Immunohistochemistry
Paraffin-embedded tissues were used to detect cell proliferation (with Ki67) and
apoptosis (with cleaved caspase-3). Sections were deparaffinized sequentially in
xylene and declining grades of ethanol prior to rehydration and transferred to PBS.
After antigen retrieval with citrate buffer (pH 6.0), the sections were blocked with 3%
hydrogen peroxide in methanol and protein blocker at room temperature. The sections
were then incubated with the Ki-67 (1:200; DakoCytomation) and monoclonal mouse
antibody against cleaved caspase-3 (1:200; Biocare Medical, Concord, CA) overnight
at 4°C. After being washed with PBS, sections were incubated with horseradish
peroxidase-conjugated rat anti-mouse immunoglobulin G2a (1:100; Serotec, Harlan
Bioproducts for Science, Madison, WI) for Ki67 staining for 1 hour.
CD31 staining was performed on frozen sections. Sections were fixed in cold
acetone for 15 min, washed with PBS, blocked with protein blocker (4% fish gel), and
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then incubated with rat monoclonal anti-mouse CD31 (1:800, PharMingen, San Diego,
CA) overnight at 4°C. After washing the slides with PBS, we added the appropriate
horseradish peroxidase–conjugated secondary antibody in blocking solution for one
hour at room temperature. Slides were developed with 3, 3”-diaminobenzidine
chromogen (Invitrogen, Carlsbad, CA) and counterstained with Gil’s No. 3 hematoxylin
(Sigma-Aldrich).
For quantification of CD31, Ki67, and cleaved caspase-3 expression, five
samples from each group were examined. To quantify microvessel density for each
sample, the microvessels within five randomly selected 0.159-mm2 fields at x200 were
counted. A single microvessel was defined as a single cell or a discrete cluster of cells
stained positive for CD31. To quantify Ki67 expression and cleaved caspase 3, the
percentage of positive cells was determined in five random fields at x200 magnification.

In vitro apoptosis assay
For this assay, 150,000 cells were in each well of a six well plate, targeting
approximately 50% confluence in serum-containing medium. After daily treatment with
IC50 doses of MSC2363318A, cell viability was assessed via flow cytometry using
Annexin V and 7-amino-actinomycin-D staining (BD Pharmingen, Franklin Lakes, NJ).
Cells were harvested, washed, incubated for 20 minutes with PE-Annexin V and 7amino-actinomycin-D according to the manufacturer’s instructions, and then subjected
to flow cytometry.

19

In vitro proliferation assay
Cells were plated in six well plates with 150,000 cells per well, targeting
approximately 50% confluence in serum-containing medium. Cells were treated daily
with MSC2363318A using IC50 and IC20 doses. The percentage of proliferating cells
(defined as the percentage of cells in S-phase) were determined using the Click-iT EdU
flow cytometry kit (Invitrogen). Cells were incubated with 10 mM 5-ethynyl-2deoxyuridine for 2 hours, lifted, and washed with 1% bovine serum albumin in
Dulbecco’s PBS. The cells were fixed with 4% paraformaldehyde in Dulbecco’s PBS for
15 minutes at room temperature and then maintained for a duration not exceeding 7
days at 4oC in the dark until use. On the day flow cytometric analysis was to be
performed, the cells were washed in 1% bovine serum albumin in PBS and
permeabilized with 1x saponin-based reagent for 15 minutes at room temperature.
Using a solution containing 1x reaction buffer, CuSO4, Alexa-Fluor 488 azide dye, and
proprietary reaction buffer additive, the cells were incubated for 30 minutes at room
temperature and then subjected to flow cytometric analysis.

Development of resistant RF-24 clone
A bevacizumab-resistant cell line was derived from original parental RF-24 cell
line by exposing cells continuously to bevacizumab at (1 mg/mL) for 72 hours. After 72
hours, media was removed and the cells were allowed to recover for seven days. Cells
were maintained continuously in the presence of bevacizumab at IC50 concentrations.
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Development of YAP1 overexpressing clone
For ectopic expression of YAP1, we obtained a lentiviral plasmid corresponding
to a validated full-length wild-type YAP1 from Addgene (PLX304-YAP1-V5, ID: 42555).
We transduced Ovca432, Igrov1, and Hec1b cells with virus particles (PLX304-YAP1
and PLX304 empty plasmid control) and then selection using neomycin/G418
(InvivoGen; 600mg/ml) was carried out to establish stable cell variants.

RF-24 tube formation assay
Sensitive and resistant RF-24 cells were seeded at a density of 100,000 per well
in a six well plate and allowed to attach overnight. The culture medium was then
aspirated and replaced with fresh culture medium containing 0.5 mg/mL and cell lines
specific IC50 doses of MSC2363318A. A 96-well plate was coated with 50 µL of
Matrigel, which was allowed to solidify at 37°C for ten minutes. Next, 20,000 cells per
well were seeded on the Matrigel. The cells were incubated at 37°C for six hours. To
assess tube formation, we counted and photographed complete tubes from randomly
chosen fields using an Olympus inverted microscope connected to a digital camera.

Statistical Analysis
Continuous variables were compared with the two-sample t test (between two
groups) or with analysis of variance (ANOVA; for all groups) if normally distributed (as
determined by the Kolmogrov-Smirnov test), and the Mann-Whitney test was used if
distributions were nonparametric. A p-value of less than 0.05 from a two-tailed
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statistical test was considered statistically significant. All statistical tests were twosided.

Reverse Phase Protein Arrays (RPPA)
Igrov1, Ovcar5, Hec1B, Ishikawa ,RL95-2 KLE, RF-24 cells sensitive to
bevacizumab, and RF-24 cells resistant to bevacizumab were treated with 1 µM
MSC2363318A for 24 hours and subjected to RPPA as previously described
[60,61,62]. Cellular proteins were denatured by 1% SDS (with beta-mercaptoethanol)
and diluted in five 2-fold serial dilutions in dilution buffer (lysis buffer containing 1%
SDS). The serial diluted lysates were then arrayed on nitrocellulose-coated slides
(Grace Biolab) by Aushon 2470 Arrayer (Aushon BioSystems). Total 5808 array spots
were arranged on each slide, which included the spots corresponding to positive and
negative controls prepared from mixed cell lysates or dilution buffer, respectively.
Each slide was probed with a validated primary antibody plus a biotinconjugated secondary antibody. Only antibodies with a Pearson correlation coefficient
between RPPA and western blotting of greater than 0.7 were used in reverse phase
protein array study. Antibodies with a single or dominant band on western blotting were
further assessed by direct comparison to RPPA using cell lines with differential protein
expression or modulated with ligands/inhibitors or siRNA for phospho- or structural
proteins, respectively.
The signal obtained was amplified using a Dako Cytomation–catalyzed system
(Dako) and visualized by DAB colorimetric reaction. The slides were scanned,
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analyzed, and quantified using a customerized-software Microvigene (VigeneTech Inc.)
to generate spot intensity.
Each dilution curve was fitted with a logistic model (“Supercurve Fitting”
developed by the Department of Bioinformatics and Computational Biology in MD
Anderson Cancer Center, “http://bioinformatics.mdanderson.org/OOMPA”). This fits a
single curve using all the samples (i.e., dilution series) on a slide with the signal
intensity as the response variable and the dilution steps are independent variable. The
fitted curve is plotted with the signal intensities – both observed and fitted - on the yaxis and the log2-concentration of proteins on the x-axis for diagnostic purposes. The
protein concentrations of each set of slides were then normalized by median polish,
which was corrected across samples by the linear expression values using the median
expression levels of all antibody experiments to calculate a loading correction factor for
each sample.
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Results

PI3K/AKT pathway alterations in ovarian and uterine cancer
To determine the prevalence of PI3K/AKT pathway alterations in ovarian and
uterine cancer, TCGA was queried. An oncoprint was developed for high grade serous
ovarian cancers to incorporate the genes, AKT1, AKT2, AKT3, PTEN, RPS6KB2, and
PIK3CA (Figure 3). The majority of alterations included amplifications of AKT1, AKT2,
AKT3, and PIK3CA.

Figure 3. PI3K/AKT pathway has genes altered in 47% (n=272) of high grade
serous ovarian cancer cases from The Cancer Genome Atlas.

A similar analysis was performed from TCGA for uterine cancer, and an
oncoprint was developed with the same genes: AKT1; AKT2; AKT3; PTEN; RPS6KB2;
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and PIK3CA (Figure 4). Mutations in PTEN and PIK3CA were the dominant mutations
identified.

Figure 4. PI3K/AKT pathway has genes altered in 90% (n=216) of uterine cases
from The Cancer Genome Atlas.

Therapeutic efficacy of MSC2363318A in orthotopic models ovarian and uterine
cancer
First, we carried out a dose-finding experiment with MSC2363318A in an ovarian
model (Igrov1), whereby mice were treated with varying concentrations of drug after
tumors were established. Downstream markers were evaluated after 12, 24, and 48
hours of the last dose administration (Figure 5). A reduction in expression of
downstream p-ribosomal S6 protein and resultant increase in pAKT473 (from feedback
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loops) was observed at doses of 20 and 40 mg/kg after 24 hours. Abrogation of this
downstream inhibition was seen 48 hours after the last dose was administered.

Figure 5. Dose finding experiments with MSC2363318A in an ovarian orthotopic
model. Western blot analysis of downstream markers from tumors of mice inoculated
with Igrov1 cells and treated with vehicle, 10 mg/kg MSC2363318A, 20 mg/kg, and 40
mg/kg after 12, 24, and 48 hours after last treatment.

Therefore, daily administration of 25 mg/kg was chosen given the return of downstream
markers after 24 hours and the maximum tolerated dose was between 20 and 25
mg/kg alone and in combination with paclitaxel (Figure 6).
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Figure 6. Maximum tolerated dose experiment with MSC2363318A monotherapy
and in combination with paclitaxel on non-tumor bearing mice. Body weight
percentage differences from maximum tolerated dose experiment of non-tumor bearing
mice after daily treatment for 14 days with MSC2363318A 20, 25, and 30 mg/kg and 20
and 25 mg/kg combined with paclitaxel (4 mg/kg).

Next, we carried out a series of experiments to characterize the therapeutic
efficacy of MSC2363318A on tumor growth alone and in combination with paclitaxel, a
commonly used frontline adjuvant therapy in gynecologic malignancies. In the
SKOV3ip1 model, treatment with MSC2363318A monotherapy resulted in a 92.8%
reduction in tumor weight compared to control (p<0.01) and treatment in the
combination group with MSC2363318A paclitaxel resulted 94% reduction in tumor
weight (p<0.05) (Figure 7A). Less distant metastases were observed at necropsy in
monotherapy and combination therapy groups (Figure 7B-C) and reductions in tumor
nodules were observed in all treatment groups (Figure 7D). There was 16-17%
decrease in mouse body weight, which was not associated with any noticeable
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changes in mobility or feeding habits (Figure 7E). A reduction in downstream pribosomal S6 protein was seen in both groups treated with MSC2363318A (Figure 6F).

Figure 7. Effects of MSC2363318A on ovarian tumor growth. Mice were inoculated
with

(A-C)

SKOV3ip1

cells

intraperitoneally

and

received

vehicle

(control),

MSC2363318A (25 mg/kg oral daily), paclitaxel (4 mg/kg intraperitoneally weekly), or a
combination of MSC2363318A and paclitaxel. Tumor growth and metastatic locations
are shown. (D) Mouse weights, (E) number of metastatic nodules, and (F) western blot
analysis of downstream markers from tumors of mice inoculated with SKOV3ip1. Error
bars represent the standard error of the mean (SEM). *, P < 0,05; **, P < 0.01; and ***,
P < 0.001.
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An additional ovarian orthotopic model with Igrov1 was performed (Figure 8A-C)
with similar results in tumor growth and metastatic spread. Mice treated with
MSC2363318A had decreased weight, and combination MSC2363318A and paclitaxel
treated mice had the fewest metastatic nodules (p<0.05) (Figure 8D-E).

Figure 8. Effects of MSC2363318A on ovarian tumor growth in a second
orthotopic model. Mice inoculated with (A-C) Igrov1 cells received vehicle (control),
MSC2363318A (25 mg/kg oral daily), paclitaxel (4 mg/kg intraperitoneally weekly), or a
combination of MSC2363318A and paclitaxel beginning ten days after inoculation. The
sites of metastases were recorded and representative pictures are shown. (D) Mouse
weights and (E) the number of metastatic nodules were recorded at necropsy. Error
bars represent the standard error of the mean (SEM). *, P < 0,05; **, P < 0.01; and ***,
P < 0.001.
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Given the high prevalence of PI3K/AKT pathway activation, we also examined
the biological effects of MSC2363318A in a uterine cancer model. Specifically, ten days
following inoculation of Hec1a cells into the uterine horn, treatment with MSC2363318A
and paclitaxel was initiated. Tumor weight was reduced in all treatment groups, but
most significantly in the combination MSC2363318A and paclitaxel treatment group
(85.3% reduction, p<0.0001) (Figure 9A). Local spread to the mesentery and within the
pelvis and distant liver metastases were observed in all groups (Figure 9B-C).The most
significant reduction in distant metastatic sites occurred in combination treatment
groups (p=0.0003) (Figure 9D) There was a reduction in mouse weights in the groups
treated with monotherapy or combination MSC2363318A and paclitaxel (Figure 9E). A
reduction in downstream p-ribosomal S6 protein was seen in both groups treated with
MSC2363318A (Figure 9F).
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Figure 9. Effects of MSC2363318A on uterine tumor growth. Mice were inoculated
with (A-C) Hec1a cells via intrauterine horn injection and received vehicle (control),
MSC2363318A (25 mg/kg oral daily), paclitaxel (4 mg/kg intraperitoneally weekly), or a
combination of MSC2363318A and paclitaxel. Tumor growth and metastatic locations
are shown. (D) Number of metastatic nodules, (E) mouse weights, and (F) western blot
analysis of downstream markers from tumors of mice inoculated with SKOV3ip1. Error
bars represent the SEM. *, P < 0.05; **, P < 0.01; ***, P < 0.001; and ****, P < 0.0001.
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Biological effects of MSC2363318A on proliferation, and apoptosis
Given the robust therapeutic effects of MSC2363318A in vivo, we evaluated
potential biological effects in tumors collected at necropsy. In the SKOV3ip1 model,
treatment with combination MSC2363318A and paclitaxel resulted in the furthest
reduction of cellular proliferation as determined by Ki67 (83% reduction, p<0.0001)
(Figure 10A). Treatment with MSC2363318A alone or in combination with paclitaxel
increased cleaved caspase-3 by more than 62% (p<0.0001) (Figure 10B).
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Figure 10. Effect of MSC2363318A on proliferation and apoptosis on ovarian
tumors. SKOV3ip1 tumors were collected at the conclusion of in vivo therapeutic
experiments and immunohistochemical stains were performed to evaluated the effects
of MSC23633318A, paclitaxel, or combination therapy on cancer cell (A) proliferation
(Ki67) and (B) apoptosis (cleaved caspase-3 [CC3]) staining. Representative sections
(final magnification, ×20) are shown for the four treatment groups. The mean Ki67positive cells and mean cleaved caspase-3 cells are shown in the adjoining
graphs. Five fields per slide and at least five slides per treatment group were examined
and compared using the Student t-test. Error bars represent the SEM. *, P < 0,05; **, P
< 0.01; ***, P < 0.001, ****, P < 0.0001.

Statistically significant reductions in CD31 (p<0.05) and Ki67 (p<0.0001) with
increases in cleaved caspase-3 (p<0.001) occurred in the combination MSC2363318A
and paclitaxel treated mice inoculated with Igrov1 cells (Figure 11).
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Figure 11. Effect of MSC2363318A on apoptosis, proliferation, and angiogenesis
on ovarian tumors.

Igrov1 tumors were collected at the conclusion of in

vivo therapeutic experiments and immunohistochemical stains were performed to
evaluated the effects of MSC23633318A, paclitaxel, or combination therapy on cancer
cell (A) cancer cell angiogenesis (CD31), (B) proliferation (Ki67), and (C) apoptosis
(cleaved caspase-3 [CC3]) staining. Representative sections (final magnification, ×20)
are shown for the four treatment groups. The mean Ki67-positive cells, mean cleaved
caspase-3 cells, and average number of CD31-positive vessels per field are shown in
the adjoining graphs. Five fields per slide and at least five slides per treatment group
were examined and compared using the Student t-test. Error bars represent the SEM.
*, P < 0,05; ***, P < 0.001, ****, P < 0.0001.

In the Hec1a model, all treatment groups had a statistically significant reduction
in Ki67, but this effect was most pronounced in the combination MSC2363318A and
paclitaxel group (52.8%, p<0.0001) (Figure 12A). Treatment with MSC2363318A alone
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or in combination with paclitaxel led to a 33-45% increase in cleaved caspase-3
(p<0.01) (Figure 12B).

Figure 12.
tumors.

Effect of MSC2363318A on proliferation and apoptosis on uterine

Hec1a tumors were collected at the conclusion of in vivo therapeutic

experiments and immunohistochemical stains were performed to evaluated the effects
of MSC23633318A, paclitaxel, or combination therapy on cancer cell (A) proliferation
(Ki67) and (B) apoptosis (cleaved caspase-3 [CC3]) staining. Representative sections
(final magnification, ×20) are shown for the four treatment groups. The mean Ki67positive cells and mean cleaved caspase-3 cells are shown in the adjoining
graphs. Five fields per slide and at least five slides per treatment group were examined
and compared using the Student t-test. Error bars represent the SEM. **, P < 0.01; and
****, P < 0.0001.
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In vitro effect of MSC2363318A in ovarian and uterine cancer cells lines
Cell lines were characterized by mutation status, and we hypothesized that
those mutations leading to activation of the PI3K/AKT pathway (such as PTEN
inactivating mutations and PIK3CA mutations) would be the most sensitive to
MSC2363318A inhibition (Table 3).
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Table 3. Mutation status of ovarian and uterine cancer cell lines [63].

The effect of MSC2363318A on a panel of ten ovarian cancer cell lines was
tested and the median inhibitor concentration (IC50) ranged from 0.7 to 12.9 µM
(Figure 13). Ovca432 was identified as the most sensitive (IC50 of 0.7 µM) and
SKOV3ip1 was the most resistant (IC50 was 12.9 µM).
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Figure 13. Effects of MSC2363318A on ovarian cancer cell lines. Cell viability after
treatment with MSC2363318A between 0 to 50 µM for 96 hours and mean inhibitory
concentration (IC50) after treatment with MSC2363318A in ovarian cancer cell lines.
Error bars represent the standard error of the mean (SEM).

The viability of a panel of nine uterine cancer cell lines were evaluated after
treatment with MSC2363318A and the IC50 ranged from 0.0004 to 33.8 µM (Figure
14). AN3CA and KLE were identified as the most sensitive and resistant cell lines,
respectively.
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Figure 14. Effects of MSC2363318A on uterine cancer cell lines. Cell viability after
treatment with MSC2363318A between 0 to 50 µM for 96 hours and mean inhibitory

concentration (IC50) after treatment with MSC2363318A in uterine cancer cell lines.
Error bars represent the SEM.

Due to the inhibition of tumor growth and proliferation, we tested these effects in
vitro using resistant (defined as IC50 ≥ 5 µM) ovarian and uterine cancer cell lines,
SKOV3ip1 and Ishikawa. We observed significantly decreased proliferation in both cell
lines when treated daily at the previously calculated concentrations that inhibited 20%
of cell growth (IC20) and IC50 doses (Figure 15).
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Figure 15. Effects of MSC2363318A on resistant ovarian and uterine cancer cell
line proliferation. Percentage of EdU incorporation in SKOV3ip1 and Ishikawa cells
treated daily with control (PBS) and MSC2363318A at cell line specific IC20 and IC50
concentrations measured after 72 hours. Error bars represent the standard error of the
mean (SEM). *, P < 0,05; and **, P < 0.01.

This was also validated in sensitive ovarian and uterine cancer cell lines, Igrov1
and Hec1b, respectively, at both concentrations (Figure 16).

Figure 16. Effects of MSC2363318A on sensitive ovarian and uterine cancer cell
line proliferation. Percentage of EdU incorporation in Igrov1 and Hec1b cells treated
daily with control (PBS) and MSC2363318A at cell line specific IC20 and IC50
concentrations measured after 72 hours. Error bars represent the SEM. **, P < 0.01.
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Next, we examined the molecular signaling events involved in the PI3K/AKT
pathway after treatment with varying concentrations of MSC2363318A. The expression
level of downstream target, p-ribosomal S6 protein, was reduced after treatment in
SKOV3ip1 (Figure 17) at concentrations above 100 nM.

Figure 17. Effect of MSC2363318A concentration on downstream markers in the
PI3K/AKT pathway. Western blot analysis of downstream and pathway markers after
treatment of SKOV3ip1 cells with 0, 0.01, 0.1, 0.5, 1, 5, and 10 µM concentrations of
MSC2363318A after 24 hours.

This duration of this effect was between 1 and 24 hours after treatment of SKOV3ip1
cells with 1 µM MSC2363318A (Figure 18).
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Figure 18.

Effect of time on MSC2363318A on downstream markers in the

PI3K/AKT pathway. Western blot analysis of downstream markers after treatment of
SKOV3ip1 cells treated with 1 µM MSC2363318A for times specified.

Paclitaxel, a commonly used chemotherapeutic used in the frontline and
recurrent setting in ovarian and uterine cancer, was tested in combination with
MSC2363318A and contributed to the most profound inhibition of tumor growth and
metastases in vivo, so the effect of combination treatment was tested in vitro. MTT
analysis demonstrated a dose-dependent decrease in cell viability after combination
therapy with paclitaxel and IC20 and IC50 concentrations of MSC2363118A. The
combination index (CI) was obtained after performing an Isobologram analysis, which
showed synergistic cytotoxicity in Ishikawa and SKOV3ip1 cells between these two
treatments (Figure 19A-B).
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Figure 19. In vitro effects of MSC2363318A and paclitaxel in resistant ovarian and
uterine cancer cell lines. (A) SKOV3ip1 and (B) Ishikawa were treated with different
concentrations of paclitaxel alone or in combination with the cell line specific IC20 or
IC50 for 96 hours followed by MTT analysis to determine percent cell viability. Error
bars represent the SEM. The combination index (CI) was calculated after performing
isobologram analysis. A CI of < 1.0 indicates synergism, a CI of 1 indicates additive
activity and a CI > 1.0 indicates antagonism.

The only other cell line, which showed similar synergy of paclitaxel and
MSC2363318A, was in the treatment of uterine cancer cell line, SKUT2 (Figure 20A).
Sensitive ovarian and uterine cancer cell lines, Igrov1 and Hec1b, suggested an
additive effect when treated concurrently with paclitaxel and MSC2363318A at IC20
and IC50 doses (Figure 20B-C).
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Figure 20. In vitro effects of MSC2363318A and paclitaxel in sensitive ovarian and
uterine cancer cell lines. (A) SKUT2, (B) Igrov1, and (C) Hec1b were treated with
different concentrations of paclitaxel alone or in combination with the cell line specific
IC20 or IC50 for 96 hours followed by MTT analysis to determine percent cell
viability. The combination index (CI) was calculated after performing isobologram
analysis for SKUT2. A CI of < 1.0 indicates synergism, a CI of 1 indicates additive
activity and a CI > 1.0 indicates antagonism. Error bars represent the SEM.
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Combination MSC2363318A with paclitaxel also contributed to a statistically
significant increase in apoptosis rates in SKOV3ip1 and Ishikawa (Figure 21).

Figure 21. In vitro effects of MSC2363318A and paclitaxel in ovarian and uterine
cancer cell lines on apoptosis. Apoptosis assay of SKOV3ip1 and Ishikawa cells
treated with cell line specific IC50 doses of MSC2363318A, paclitaxel, and combination
therapy after 72 hours. Error bars represent the SEM. *, P < 0,05; **, P < 0.01; and ***,
P < 0.001.

RPPA identifies YAP1 as a predictor of in vitro response to MSC2363318A
To identify potential markers of response to MSC2363318A, we used RPPA to
quantify the protein expression of genes that are modulated after treatment in Igrov1
and Ovcar5 ovarian cancer cell lines and Hec1B, Ishikawa, KLE, and RL-952 uterine
cancer cell lines (Figure 22).
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Figure 22. Differential expression of proteins in the PI3K/AKT/P70S6 signaling
pathway after MSC2363318A treatment as detected by reverse-phase protein
array. Heatmap of proteins whose expression was different before and after treatment
with MSC2363318A (1 µM) for 18 hours.

Protein and phosphorylated protein changes were analyzed and uploaded into
Ingenuity Pathway Analysis (IPA) to perform a network analysis. We identified the top
networks that were activated in the ratio of resistant to sensitive cells lines (Table 4).

Table 4. Top 10 networks in resistant to sensitive ovarian and uterine cancer cell
lines.
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Given the robust in vitro and in vivo effects on angiogenesis, we further
investigated the upregulated pro-angiogenic signaling molecules by a network overlaid
with the ratio of resistant to sensitive total protein changes (Figure 23).

Figure 23.

Upregulated pro-angiogenic singaling molecules by a network

overlaid with the ratio of resistant to sensitive total protein change using
Ingenuity Pathway Analysis.

47

After a further analysis of only resistant cell lines with and without
MSC2363318A treatment, we observed an increase in total YAP1 (Figure 24A)
whereas in the ratio of treated to untreated sensitive cell lines, there was
downregulation of YAP1 (Figure 24B).

Figure 24. Differential expression of angiogenic proteins in the PI3K/AKT/P70S6
signaling pathway after MSC2363318A treatment as detected by reverse-phase
protein array. (A) Pro-angiogenic signaling molecules by a network overlaid with the
ratio of treated to untreated total protein changes in resistant and (B) sensitive cell lines
using Ingenuity Pathway Analysis.
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We plotted the logarithmic ratio values for YAP1 and pYAP1 from the cells lines
using the RPPA data of the treated over untreated ratio (Figure 25). Total YAP1 was
more highly expressed in resistant cell lines.

Figure 25. Logarithmic ratio values for YAP1 and pYAP1 in cancer cell
lines. Resistant cell lines were classified by an IC50 ≥ 5 µM. Error bars represent the
SEM.

We validated our findings from the RPPA by western blot analysis (Figure 26).
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Figure 26. Western blot validation using samples submitted for RPPA.

YAP1 expression was evaluated in a panel of ovarian (Figure 27A) and uterine
(Figure 27B) cancer cell lines and a Spearman’s correlation was performed (R=0.675,
p=0.0015), suggesting that more resistant cell lines have higher YAP1 expression and
vice versa (Figure 27C). YAP1 expression was also evaluated by western blot (Figure
27D), and there was no association between YAP1 protein expression and IC50
(Figure 27E).
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Figure 27. Correlation between YAP1 and MSC2363318A IC50 in ovarian and
uterine cancer cell lines. (A) Relative expression of YAP1 in uterine (normalized to
post-menopausal endometrial scrapings) and (B) ovarian cancer cell lines (normalized
to HIO-180). Quantification was done using the qRT-PCR method. (C) Pearson
correlation between YAP1 expression and cell line specific IC50 for MSC2363318A. (D)
YAP1 expression in a panel of ovarian and uterine cancer cell lines. (E) Spearman’s
correlation was performed between YAP1 protein expression and MSC2363318A
IC50. Error bars represent the SEM.

To address the role of YAP1 overexpression and resistance to MSC2363318A,
we transfected Ovca432, Igrov1, and Hec1b cells with YAP1 or empty vector and
characterized them by western blot (Figure 28A). There were minimal differences in
apoptotic rates after treatment with MSC2363318A in the cell lines with empty vector or
YAP1 (Figure 28B).
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Figure 28.

Characterization of YAP1 overexpressing clones and effects on

apoptosis after MSC2363318A treatment. (A) Western blot of YAP1 expression in
transfected cell lines. (B) Cell viability with Ovca432-plx versus Ovca432-YAP1, Igrov1plx versus Igrov1-YAP1, and Hec1b-plx versus Hec1b-YAP1 after concentrations of
MSC2363318A between 0 and 50 µM were added for 96 hours. Error bars represent
the SEM. *, P < 0,05; **, P < 0.01; ***, P < 0.001; and ****, P < 0.0001.

Anti-angiogenic effects of MSC2363318A and bevacizumab
To address whether MSC2363318A affects endothelial cells in vitro, we
assessed endothelial cell tube formation. Treatment of sensitive RF-24 endothelial cells
with MSC2363318A resulted in a 67.2% (p<0.0001) decrease in the number of nodes

52

formed relative to the control group (Figure 29). Combination MSC23663318A and
bevacizumab resulted in an 82.8% reduction (p<0.0001) relative to control.

Figure 29. In vitro effects of MSC2363318A in combination with anti-angiogenic
therapy in a sensitive endothelial cell line. Representative pictures of endothelial
vessel formation of sensitive and bevacizumab-resistant RF-24 cells and quantification
of the number of number of nodes (points at which where three or more elongated cells
meet) formed on the gel matrix after prior treatment with 0.5 µg of bevacizumab,
MSC2363318A with the cell line specific IC20, or combination therapy. n = 3 wells per
group and mean number of nodes is quantified from five pictures per well. Error bars
represent the SEM. ****, P < 0.0001 as determined by the Student t test.

Clinically, patients develop resistance to anti-angiogenic therapies, so we
established a bevacizumab resistant RF-24 clone (Figure 30A) to evaluate the
effectiveness of MSC2363318A in the resistant setting. Cellular viability was assessed
for the sensitive and resistant RF-24 cell lines (Figure 30B) and the sensitive line had a
statistically significant lower IC50 (p<0.001). Endothelial cell tube formation was
assessed in the resistant RF-24 cell line after treatment with MSC2363318A alone and
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in combination with bevacizumab, and there were resultant decreases in the nodes
formed in the groups treated with MSC2363318A (Figure 30C).

Figure 30. In vitro effects of MSC2363318A in combination with anti-angiogenic
therapy in a resistant endothelial cell line. (A) Viability of sensitive and
bevacizumab-resistant RF-24 cells after treatment with bevacizumab at 0, 0.125, 0.25,
0.5, and 1 µg for 96 hours and (B) MSC2363318A between 0 to 50 µM ± 0.5 mg of
bevacizumab

for

96

hours

and

mean

inhibitory

concentration

(IC50).

(C)

Representative pictures of endothelial vessel formation of bevacizumab-resistant RF24 cells and quantification of the number of number of nodes (points at which where
three or more elongated cells meet) formed on the gel matrix after prior treatment with
0.5 mg of bevacizumab, MSC2363318A with the cell line specific IC20, or combination
therapy. n = 3 wells per group and mean number of nodes is quantified from five
pictures per well. Images were taken at 100× magnification. Error bars represent the
SEM. **, P < 0.01; and ***, P < 0.001 as determined by the Student t test.
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We observed a significant reduction in percentage EdU incorporation in both the
sensitive and resistant RF-24 cell lines treated with combination MSC2363318A and
bevacizumab suggesting a potentially additive benefit in both the sensitive and
resistant setting (Figure 31A). Treatment of resistant and sensitive RF24 cells with 1
µM of MSC2363318A led to a reduction of p-S6 ribosomal protein and increase in
pAKT473 (Figure 31B).

Figure 31. Effect of treatment with MSC2363318A in combination with
bevacizumab

on

proliferation

and

downstream.

(A)

Percentage

of

EdU

incorporation in sensitive and bevacizumab-resistant RF-24 cells after treatment
without (-) and with (+) bevacizumab and cell line specific IC50 concentrations of
MSC2363318A after 72 hours. (B) Western blot of downstream markers after sensitive
and resistant RF-24 cells were treated with 1 µM MSC2363318A for 24 hours.
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The addition of MSC2363318A and bevacizumab to resistant RF-24 cells led to
a 78.5% reduction in the MSC2363318A IC50, which became less than the
MSC2363318A IC50 of sensitive RF-24 cells (Figure 32).

Figure 32. Effect on MSC2363318A IC50 in resistant and sensitive RF-24 cells
with and without bevacizumab. Viability of sensitive and bevacizumab-resistant RF24 cells after treatment with MSC2363318A between 0 to 50 µM ± 0.5 mg of
bevacizumab for 96 hours and mean inhibitory concentration (IC50). Data represent
average of triplicate measurements and error bars represent the SEM. ****, P < 0.0001
as determined by the Student t test.

Given the effects of MSC2363318A on angiogenesis in vitro, we evaluated the
effects on angiogenesis in vivo by calculating the microvessel density (MVD) of tumors
harvested at the conclusion of the therapy experiments. In the SKOV3ip1 tumor model,
treatment with MSC2363318A alone or in combination with paclitaxel decreased MVD
by 61.8% (p<0.05) and 63.1% (p<0.01), respectively (Figure 33A). Similar effects of
CD31 were observed in the Hec1a orthotopic murine model with significant reductions
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in MSC2363318A (36%, p<0.05) and combination MSC2363318A groups (32.4%,
p<0.05) (Figure 33B).

Figure 33. In vivo effects of MSC2363318A on angiogenesis in combination with
paclitaxel. Immunohistochemistry was performed to evaluate the effects of
MSC23633318A, paclitaxel, or combination therapy on cancer cell angiogenesis
(CD31). Representative sections (final magnification, ×20) are shown for the four
treatment groups with the average number of CD31-positive vessels per field in mice
inoculated with SKOV3ip1 (A) and Hec1a (B). Error bars represent the SEM. *, P <
0,05; **, P < 0.01.

We further investigated the effects of MSC2363318A in combination with an
anti-angiogenic therapy, bevacizumab. Substantial reductions in tumor weight were
observed in all groups but most profound (96% reduction compared to control,
p<0.0001) in the group treated with MSC2363318A and bevacizumab (Figure
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34A). Less distant metastases were observed in monotherapy and combination
therapy groups (Figure 34B-C). A significant reduction in mouse weight was present in
the combination bevacizumab and MSC2363318A group (Figure 34D). Tumor nodules
were significantly decreased observed in all treatment groups Figure 34E).
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Figure 34. In vivo effects of MSC2363318A in combination with anti-angiogenic
therapy in an ovarian orthotopic model. Mice inoculated with (A-C) HeyA8 ovarian
cancer cells received vehicle (control), MSC2363318A (25 mg/kg oral daily),
bevacizumab (6.25 mg/kg intraperitoneally twice weekly), or a combination of
MSC2363318A and bevacizumab beginning ten days after inoculation. Tumor size and
sites of metastases were recorded and representative pictures are shown.

(D-E)

Mouse weights and number of metastatic nodules from mice inoculated with HeyA8
received vehicle, MSC2363318A, bevacizumab, or a combination of MSC2363318A
and bevacizumab beginning ten days after inoculation. Error bars represent the SEM. *,
P < 0,05; **, P < 0.01; ***, P < 0.001; and ****, P < 0.0001.

In the HeyA8 tumors, there was a 57.7% (p<0.05) and 59.5% (p <0.01)
reduction in MVD in the MSC2363318A monotherapy and combination therapy groups,
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respectively (Figure 35). Similar to the other orthotopic models, treatment with
MSC2363318A and bevacizumab resulted in decreased cellular proliferation and
increased apoptosis (Figure 35).

Figure 35. Effects of MSC2363318A and bevacizumab on angiogenesis,
proliferation and apoptosis in an ovarian orthotopic model. Immunohistochemistry
was performed to evaluate the effects of MSC23633318A, bevacizumab, or
combination therapy on MVD (CD31), proliferation (Ki67), and apoptosis (cleaved
caspase-3 [CC3]) staining. Representative sections (final magnification, ×20) are
shown for the four treatment groups. Mean Ki67-positive cells mean cleaved caspace-3
cells, and average number of MVD are shown in the adjoining graphs. Five fields per
slide and at least five slides per treatment group were examined and compared using
the Student t-test. Error bars represent the SEM. *, P < 0,05; **, P < 0.01; ***, P <
0.001; and ****, P < 0.0001.
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Discussion
The key findings in this manuscript are that dual inhibition of AKT and P70S6K
by the novel inhibitor, MSC2363318A, has therapeutic efficacy in multiple preclinical
models by enhancing cellular apoptosis, inhibiting proliferation, and reducing the
formation of vasculature.

Synergy was observed in both cancer types with the

combination of MSC2363318A and paclitaxel. Addition of MSC2363318A to antiangiogenic therapy potentiated the effects of bevacizumab and restored sensitivity in
the resistant setting. Finally, we identified YAP1 as a predictor of sensitivity to
inhibition with MSC2363318A.
The frequent activation of the PI3K/AKT pathway in malignancies makes it a
desirable target for therapeutic intervention. The first drugs developed to target this
pathway and approved for treatment included the rapamycin analogs, which included
temsirolimus and everolimus. Mechanistically, the drugs allosterically inhibit mTORC1.
Other broad classes of inhibitors that have since been developed: (1) ATP competitive
dual inhibitors of class I PI3K and mTOR, (2) PI3K inhibitors that inhibit all four class I
PI3K isoforms (α, β, δ, and γ); (3) specific PI3K isoform inhibitors; (4) ATP competitive
inhibitors of mTOR; and (5) AKT allosteric and catalytic inhibitors [64].
The first PI3K inhibitors, including Wortmannin and LY294002, could bind all
class I PI3Ks and lead to pan-inhibition of this pathway. Due to their poor selectivity
and pharmacokinetic properties, their therapeutic potential remained limited [27].
Recent pan-class I inhibitors include GDC-0941, BKM120, and PX866. All of these are
being tested in ongoing trials for solid and hematologic malignancies including breast,
colorectal and squamous cell carcinomas, melanoma, and lymphomas [27]. Second
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generation PI3K inhibitors targeted specific PI3K isoforms and are being evaluated in
preclinical and clinical studies. GDC-0032 is specific for PI3Kα, which may spare
patients from commonly experienced metabolic abnormalities [65,66]. GSK2636771,
specific for the PI3Kβ isoform, has been studied in a variety of solid malignancies,
especially those that lack PTEN [67]. IPI-145 has been tested in several hematologic
malignancies because it preferentially targets PI3Kδ and PI3Kγ, which are the two
isoforms that are preferentially expressed on leukocytes [68]. CAL-101, which is PI3Kδ
specific, has been tested in acute myelogenous leukemia, chronic lymphocytic
lymphoma, Hodgkin’s lymphoma, non-Hodgkin’s lymphoma, and multiple myeloma
[69].
The third generation included dual PI3K/mTOR inhibitors, which target PI3K
class I isoforms, mTORC1, and mTORC2, which led to greater inhibition of this entire
pathway (19). For example, NVP-BEZ235, has been tested in renal cell and breast
cancers. This drug inhibits both ATM and DNA-PKcs and is considered to also be a
radiosensitizer. Its lack of bioavailability has prevented further development [70,71].
Three isoforms of AKT possess biologic relevance in cancer pathogenesis and
phosphorylation activates multiple downstream signaling cascades including TSC2
protein, TSC1, mTOR, BAD, and caspase-9 (20). AKT inhibitors in preclinical and
clinical

development

include

perifosine,

a

phospholipid

derivative

of

alkylphosphocholine, MK-2206, an allosteric inhibitor of AKT, RX-0201, 20-mer
antisense oligodeoxynucleotide directed against AKT, Erucylphosphocholine, PBI05204, GSK690693, and XL-418 (21). XL-418, which inhibited both AKT and P70S6K,
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was tested in a phase I clinical trial in patients with advanced solid tumors. This study
was ended due to low drug exposure (NCT00460278).
Successful targeted therapy depends on identifying biomarkers that can be used
further during clinical development. This helps to identify which patients are most likely
to respond while avoiding untoward toxicities in those patients who will not [72].
Previous data has identified gain of function mutations in PIK3CA may cause a tumor
to be more sensitive to PI3K inhibition [67]. Up to 91% of uterine cancers may harbor a
mutation or alteration in PTEN, which contributes to activation of the PI3K/AKT
pathway [22]. This may explain why KLE, which is wild type for PTEN and PIK3CA,
may be the most resistant among the uterine cell lines tested. Furthermore, Hec1b has
a mutation in PIK3CA, but not PTEN.
Despite the large number of inhibitors developed to target to this pathway, none
of these is able to induce a durable complete remission.

This is largely due to

resistance that develops and the lack of understanding behind what drives the
molecular basis of resistance, whether it is acquired or intrinsic. Proposed mechanisms
of resistance include secondary mutations, crosstalk between other pathways that then
activate survival mechanisms, and/or amplification of downstream targets within the
same targeted pathway [73]. Resistance to PI3K/AKT inhibitors under current
development has been linked to the negative feedback loops. Within one of these
loops, inhibition of mTORC1 leads to the upregulation of tyrosine kinase receptors
(such as platelet derived growth factor receptor [PDGFR] or insulin receptor substrate-1
[IRS-1]). This leads to an increase in phosphorylation of AKT at the serine473 residue.
Within a second loop, inhibitor of mTORC1 leads to further PI3K-Ras activation, which
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thereby increases the activation of the MAPK pathway [74].

Activation and

amplification of MYC may also contribute to inherent resistance of therapeutics that
targets this pathway. This parallel pathway may have increased MYC activation
through PDK-1 dependent MYC phosphorylation and abrogate the effects of an
inhibitor of the PI3K/AKT pathway [75]. This feedback inhibition provides the rationale
for further development of MSC2363318A, which inhibits AKT1, AKT3, and P70S6K.
Dual inhibition of AKT and further downstream abrogates the negative feedback loop
activation that earlier inhibitors of this pathway caused.
One of the most important issues to consider during drug development remains
drug toxicities, side effects, and potentially “off-target” effects. The majority of side
effects related to therapeutics targeting the PI3K/AKT pathway have been mild to
moderate and able to be managed with supportive, expectant management alone [76].
The reported dose limiting side effects from early clinical trials include hyperglycemia,
gastrointestinal side effects (including nausea, vomiting, diarrhea, and anorexia),
stomatitis, and maculopapular rash [77]. Some of these side effects can be considered
“off-target,” however most are related to the primary mechanism of action. For
example, PI3K inhibitors cause hyperglycemia because this pathway is involved in the
insulin signaling pathway. Side effects warrant careful attention and may be useful
during dose escalation studies and further clinical decision making [78]. Dual inhibitors
of PI3K and mTORC1/2 have been reported to cause a wider variety of off-target
effects, such as elevated transaminases and fatigue, but their utility has not been
hampered. During our treatment with MSC2363318A, we observed weight loss in the
mice receiving treatment, but no behavioral effects or direct side effects were observed.
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Our preclinical data indicate that MSC2363318A promotes apoptosis, inhibits
proliferation, and restores sensitivity to bevacizumab resistant tumors in both ovarian
and uterine cancer. The first phase I trial that is an open-label, non-randomized, dose
escalation, trial to explore the safety, tolerability, pharmacokinetic, pharmacodynamics,
and clinical activity of MSC2363318A in patients with advanced malignancies has
recently opened (NCT01971515).

While the niche of this compound remains

undetermined, future directions include administration of MSC2363318A as an adjuvant
therapy in combination with taxane-based therapy after surgical cytoreduction. Other
alternatives include combining MSC2363318A with bevacizumab or other antiangiogenic therapies in patients whose tumors have developed resistance so that
sensitivity to bevacizumab can be restored. Finally, the identification of high YAP1
expression identifies those tumors that are most sensitive to inhibition by
MSC2363318A. By identifying the subset of patients whose tumors would be most
sensitive to dual AKT/P70S6K inhibition, lower treatment doses could be considered,
overtreatment of patients who would not benefit will be avoided, and untoward toxicities
in patients who will not respond, would be prevented.

Future directions and translational relevance
The challenge of targeted therapies directed toward the PI3K/AKT pathway is
multifaceted. With the advent of so many inhibitors, a rational approach should be
developed to determine in which contexts each inhibitor should be used. This would
include clinical and prognostic factors as well as the genomic composition of the
tumors.
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With regard to translating my research findings into clinical trials, rational
combinations should be considered and whether a PI3K/AKT inhibitor should be added
to standard of care chemotherapy in the adjuvant setting. One way in which this can be
evaluated is through “window-of-opportunity” trials. In this trial design, women with
newly diagnosed ovarian cancer (as confirmed by pathologic biopsy), would receive a
study drug such as MSC2363318A for one to two weeks between the time of biopsy
and surgical resection.

This allows for physician-scientists to evaluate the targets

modulated by the study drug after a given period of exposure time and determine if
additional modifications to clinical development should be considered. Additionally,
pharmacokinetic assessments can be made on post-resection samples. Alternatively, if
the woman received neoadjuvant therapy instead of upfront surgical resection, the
biological agent can be added along with traditional chemotherapy for a longer period
of time prior to surgery. One of the primary reasons alternative clinical trial designs
must be considered is that traditional ways of evaluating response through Response
Evaluation Criteria in Solid Tumors (RECIST) criteria, invalid conclusions may be
reached about the potential benefit of an investigational agent. Pre-surgical studies
such as these may further expedite approval of these agents because they shed light
on the biologic effect of the drug early in the development, rather than waiting for the
results of Phase II and III studies. Furthermore, they contribute to the validation of
markers that will help clinicians identify which patients will best benefit from this type of
therapy. Other possibilities include use of inhibitors as a maintenance therapy after
complete surgical resection and after frontline therapy (e.g., trial designs used in
GOG218 and ICON7 – details mentioned in Introduction). In this type of trial design,
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women would be assigned to receive standard chemotherapy after surgical
cytoreduction with and without the investigational agent during the therapy and with
and without the agent after chemotherapy has ended for a pre-specified length of time.
Due to the activation of the PI3K/AKT pathway in angiogenesis and the resistant
endothelial studies from this study, consideration could also be given to the addition of
MSC2363318A to bevacizumab. The work presented here suggests that the addition of
MSC2363318A to bevacizumab in the resistant setting may resensitize the tumor cells
to therapy.
Due to the emergence of resistance to anti-angiogenesis therapy clinically, we
are currently investigating whether MSC2363318A can overcome such resistance, and
we are currently studying this in a model of adaptive resistance. This model requires
intraperitoneal injections of luciferase-labeled cells to allow for confirmation of tumor
establishment with bioluminescence imaging with randomization to two treatment
groups: (1) control and (2) bevacizumab treatment. After three weeks of continuous
bevacizumab treatment and weekly imaging, mice will be subsequently divided into
bevacizumab-sensitive and bevacizumab-resistant groups based on tumor growth as
evidenced by increased bioluminescence intensity in previously stable tumor burden.
At the emergence of resistance in the previously sensitive group, MSC2363318A is
added to the bevacizumab treatment. The combined treatment will continued until mice
become moribund. We hypothesize that the additional of MSC2363318A at the
emergence of resistance will halt tumor growth and prolong survival, as compared to
either control or bevacizumab treatment alone.
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As a follow-up to this preclinical study, we could identify women whose tumors
“breakthrough” bevacizumab in the recurrent setting. Women could subsequently be
randomized to receive continued bevacizumab with the addition of MSC2363318A or
another standard therapy for recurrent disease by the National Comprehensive Cancer
Network (NCCN) guidelines.

Using more frequent imaging and markers of clinical

response, progression free survival and overall survival of these two groups could be
compared.
Other important niches to consider would be the effect of MSC2363318A on
bulky tumors. This pre-clinical model is also currently being investigated after injection
of luciferase-labeled uterine cells that were injected into the uterine horn.

After

established, measurable tumor growth is recorded by IVIS imaging, mice were
randomized to four different treatment groups:

(1) vehicle; (2) MSC2363318A; (3)

paclitaxel; and (4) MSC2363318A and paclitaxel.

Weekly quantifications of tumor

volumes are made and mice are sacrificed with they become moribund. The effect of
MSC2363318A as a monotherapy and in combination with chemotherapy on survival
must be further investigated.
With the ever increasing number of targeted therapies, the addition of
MSC2363318A with other novel agents should be tested.

This includes poly-ADP

ribose polymerase (PARP) inhibitors recently approved for recurrent ovarian cancer in
BRCA mutation carriers. Preclinical work has shown that PI3K inhibition is correlated
with the loss of homologous recombination repair, which increases DNA damage, and
could lead to further sensitization of tumor cells by PARP inhibition [79]. An ongoing
phase I trial combines olaparib, a PARP inhibitor, with a PI3K inhibitor in patients with
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high grade serous ovarian cancer and triple negative breast cancer [80]. This
combination has been already investigated in pre-clinical models of triple negative
breast cancer.

In this study, a pan-class IA PI3K inhibitor (NVP-BKM120) was

combined with olaparib, which delayed tumor doubling in the combination therapy
groups [79,81]. While olaparib is currently only approved for women with BRCA
mutations, the addition of a PI3K/AKT inhibitor such as MSC2363318A could potentially
make tumor cells without a somatic or germline BRCA mutation sensitive even more
sensitive to PARP inhibition.

Study limitations
Here, we show compelling evidence that MSC2363318A promotes anti-tumoral
growth and proliferation in pre-clinical models of ovarian and uterine cancer. High
YAP1 expression is correlated with resistance to apoptosis after treatment with
MSC2363318A.

The mechanism of how YAP1 contributes to resistance remains

unknown at this point. Profiling resistant cells such as SKOV3ip1, Ishikawa, and KLE
after YAP1 knockdown and performing genomic profiles would give further insight into
this mechanism. In cells that were transfected to overexpress YAP1, there was a slight
protection against cell death, but this slight increase does not account for the protection
afforded by nontransformed cells that overexpress YAP1.
Another limitation to this work is that only ovarian and uterine models were
investigated. The PI3K/AKT pathway is one of the most frequently activated signaling
pathways in cancer, so MSC2363318A may have broader effects on tumor growth in
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other solid malignancies. Patient derived xenograft models should be considered in
future studies.

Implications
On the basis and considerations described here, we show that MSC2363318A
has therapeutic efficacy in multiple ovarian and uterine orthotopic models. Reductions
in tumor weight, number of metastatic sites and nodules were observed without dose
limiting side effects.

This dual AKT1, AKT3, and P70S6K inhibitor inhibits cellular

proliferation, promotes tumoral apoptosis, and decreases small vessel formation. The
efficacy observed makes MSC2363318A a novel small molecule therapeutic that is
worthy of further clinical development in patients in the frontline in combination with
paclitaxel or in the recurrent setting. Our RPPA and in vitro validation suggest that
YAP1 represents a biomarker that may identify those patients whose tumor may be
most sensitive to this type of dual inhibition. Further, mechanistic studies are needed
to better understand the molecular biology between these two pathways.
Moreover, given our findings in vivo and the effects of MSC2363318A on
angiogenesis, we showed that in the resistant setting, the additional of MSC2363318A
may allow for resensitization to anti-angiogenic agents. The addition of MSC2363318A
to patients who have become resistant to bevacizumab may improve survival and
prolonged, durable responses.
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Conclusions:
Our preclinical data demonstrate that MSC2363318A may be therapeutically
beneficial to ovarian and uterine cancer patients in combination with taxane-based
therapies or anti-angiogenic therapies in the sensitive and resistant setting. YAP1
represents a potential predictive biomarker for predicting sensitivity of the cancer
response to this treatment.
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